Jianzhong Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianzhong Zhou has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Cheng Zhang
Department of Cardiothoracic Surgery The First Affiliated Hospital of Chongqing Medical University Chongqing China
2 shared publicationsQin Duan
The First Branch The First Affiliated Hospital of Chongqing Medical University Chongqing China
2 shared publications- Yue Shao
Department of Cardiothoracic Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publications Changfen Wang
Department of Cardiology, Qian Xi Nan People's Hospital, Zunyi, CHN
1 shared publicationDi Gu
Chongqing Med Univ, Dept Internal Med, Div Cardiol, Affiliated Hosp 1, Chongqing 400016, Peoples R China
1 shared publication- Fuwei Liu
Department of Cardiology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University
1 shared publication
Latest Publications
- Open Access
- 14 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1114
Uncovering the Targets of Pueraria Associated with Programmed Cell Death and the Construction of a Diagnostic Model in Septic Cardiomyopathy
Background: Septic cardiomyopathy (SCM) is a fatal sepsis-induced dysfunction. While Pueraria (Pue) exhibits protective effects in sepsis, its regulatory role regarding programmed cell death (PCD) in SCM remains unclear. This study aimed to identify Pue’s PCD-related targets in SCM and construct a validated diagnostic model. Methods: We analyzed 14 PCD modalities across seven GEO transcriptomic datasets. A robust machine learning framework integrating 171 algorithm combinations built a diagnostic signature. The immune landscape was profiled using single-cell RNA sequencing and enrichment analyses. Experimental validation utilized SCM patient blood samples and heart tissues from an LPS-induced murine model. Results: Nine PCD patterns were significantly altered in SCM. Intersection analysis and machine learning identified five core Pue targets: STAT3, RIPK2, GM2A, ALOX5, and DPP4. A diagnostic model constructed with these genes achieved high AUCs across all datasets. Single-cell analysis revealed cell-type-specific expression within the myocardial immune landscape. Differential expression of these five genes was validated in both human and animal samples, correlating significantly with cardiac function indices. Conclusions: Our results demonstrate that Pueraria mitigates SCM and restores cardiac function by modulating the expression of core PCD-related targets. These targets are closely associated with the localized inflammatory response, providing potential therapeutic avenues for SCM.
- 14 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1114
Open AccessUncovering the Targets of Pueraria Associated with Programmed Cell Death and the Construction of a Diagnostic Model in Septic Cardiomyopathy
Background: Septic cardiomyopathy (SCM) is a fatal sepsis-induced dysfunction. While Pueraria (Pue) exhibits protective effects in sepsis, its regulatory role regarding programmed cell death (PCD) in SCM remains unclear. This study aimed to identify Pue’s PCD-related targets in SCM and construct a validated diagnostic model. Methods: We analyzed 14 PCD modalities across seven GEO transcriptomic datasets. A robust machine learning framework integrating 171 algorithm combinations built a diagnostic signature. The immune landscape was profiled using single-cell RNA sequencing and enrichment analyses. Experimental validation utilized SCM patient blood samples and heart tissues from an LPS-induced murine model. Results: Nine PCD patterns were significantly altered in SCM. Intersection analysis and machine learning identified five core Pue targets: STAT3, RIPK2, GM2A, ALOX5, and DPP4. A diagnostic model constructed with these genes achieved high AUCs across all datasets. Single-cell analysis revealed cell-type-specific expression within the myocardial immune landscape. Differential expression of these five genes was validated in both human and animal samples, correlating significantly with cardiac function indices. Conclusions: Our results demonstrate that Pueraria mitigates SCM and restores cardiac function by modulating the expression of core PCD-related targets. These targets are closely associated with the localized inflammatory response, providing potential therapeutic avenues for SCM.
- Open Access
Peripheral Venous Pressure Accurately Evaluates Congestion in Constrictive pericarditis
Background The primary clinical characteristic of initial constrictive pericarditis(CP) is a cardiac decreased diastolic function, which results in venous congestion, limitation of venous return, and elevated central venous pressure(CVP). Objective was to evaluate the relationship between peripheral venous pressure (PVP) and CVP with the aim to assess the diagnostic value of PVP in CP. Methods Subjects underwent invasive haemodynamic and low invasive peripheral venous pressure assessment and also underwent physical examination, biochemical indices to assess venous congestion and echocardiography to assess cardiac structure and function. Patients were divided into 2 groups by CVP > 22 cmH2O(Modal 1 defined as CVP > 22 cmH2O; Modal 2 defined as CVP≦22cmH2O). Results Of the 36 patients, PVP and CVP had a significant positive association (Pearson’s = 0.831; P < 0.0001), with CVP = 0.962 + 0.907PVP as the regression equation.PVP was negatively correlated with FIB-4 (Pearson’s = −0.425; P=0.01), while it was not statistically significantly correlated with Pro-BNP, albumin, serum Na, hematocrit, hemoglobin, total bilirubin, direct bilirubin, or ARPI. Modal 1 and 2 groups were separated based on CVP > 22 cmH2O. By comparing the area under the curve (AUC) of the participants’ working mass, it was definitively established that 24 cmH2O was the ideal PVP threshold for the diagnosis of CP. Conclusions In Constrictive Pericarditis, PVP is a reliable, minimally invasive, and accurate technique for calculating CVP, which is remarkably positively correlated with CVP. Measurement of PVP is therefore important in the assessment of congestion and helps in the early diagnosis of Constrictive Pericarditis when PVP is greater than 24 cmH2O.
Open AccessPeripheral Venous Pressure Accurately Evaluates Congestion in Constrictive pericarditis
Background The primary clinical characteristic of initial constrictive pericarditis(CP) is a cardiac decreased diastolic function, which results in venous congestion, limitation of venous return, and elevated central venous pressure(CVP). Objective was to evaluate the relationship between peripheral venous pressure (PVP) and CVP with the aim to assess the diagnostic value of PVP in CP. Methods Subjects underwent invasive haemodynamic and low invasive peripheral venous pressure assessment and also underwent physical examination, biochemical indices to assess venous congestion and echocardiography to assess cardiac structure and function. Patients were divided into 2 groups by CVP > 22 cmH2O(Modal 1 defined as CVP > 22 cmH2O; Modal 2 defined as CVP≦22cmH2O). Results Of the 36 patients, PVP and CVP had a significant positive association (Pearson’s = 0.831; P < 0.0001), with CVP = 0.962 + 0.907PVP as the regression equation.PVP was negatively correlated with FIB-4 (Pearson’s = −0.425; P=0.01), while it was not statistically significantly correlated with Pro-BNP, albumin, serum Na, hematocrit, hemoglobin, total bilirubin, direct bilirubin, or ARPI. Modal 1 and 2 groups were separated based on CVP > 22 cmH2O. By comparing the area under the curve (AUC) of the participants’ working mass, it was definitively established that 24 cmH2O was the ideal PVP threshold for the diagnosis of CP. Conclusions In Constrictive Pericarditis, PVP is a reliable, minimally invasive, and accurate technique for calculating CVP, which is remarkably positively correlated with CVP. Measurement of PVP is therefore important in the assessment of congestion and helps in the early diagnosis of Constrictive Pericarditis when PVP is greater than 24 cmH2O.
- Top Cited PapersOpen Access
- 24 November 2024
- Published by Springer Nature in Cureus
- Vol. 16 (11) , e74333
Global, Regional, and National Burden of Cardiovascular Disease, 1990-2021: Results From the 2021 Global Burden of Disease Study
Background Cardiovascular diseases (CVD), including coronary artery disease, ischemic heart disease, stroke, cardiomyopathy, and atrial fibrillation and flutter, are the leading cause of mortality worldwide, resulting in significant economic and health costs. Recognizing trends and geographical differences in the global burden of CVD facilitates health authorities in particular nations to assess the disease burden and forecast future epidemiological trends. Public health authorities in each country can better understand the differences in disease data and, by learning from the experiences and practices of successful countries and considering the characteristics of their diseases, allocate health resources more rationally and formulate more targeted healthcare strategies to reduce the disease burden. This study aims to comprehensively assess CVD trends and geographic variations from 1990 to 2021. Methods This study focuses on analyzing global trends in the epidemiology of all-age CVD incidence and death over the past 30 years. A vital registration system, cause-of-death inference records, and a cause-of-death ensemble model (CODEm) were used to estimate cause-specific mortality for CVD, with CODEm estimates adjusted using a cause-of-death correction (CoDCorrect) algorithm. Incidence data were extracted from insurance claims and inpatient discharge sources and analyzed with Disease Modeling Meta-Regression, Version 2.1 (DisMod-MR 2.1). Data were extracted from the 2021 Global Burden of Disease Study (GBD 2021) on the number of incident cases and deaths, as well as age-standardized incidence rates (ASIR) and age-standardized death rates (ASDR) for CVD for each year from 1990 to 2021. We visualized and reported this data at the global, regional, and national levels. To explore the association between the burden of CVD and sociodemographic factors, we used the sociodemographic index (SDI), which categorizes the world's 204 nations into five SDI regions. Because the GBD results are a combination of data and estimates, 95% uncertainty intervals (UI) are provided for each count and rate (per 100,000 populations). Results Globally, the number of CVD incident cases and deaths increased from 34.74 million and 12.33 million in 1990 to 66.81 million and 19.42 million in 2021, representing a 92.3% and 57.5% rise, respectively. However, the global ASIR and ASDR for CVD have decreased by 10.4% and 34.3%, respectively, since 1990. Notably, among the 21 regions of the world, the ASIR for CVD is on a downward trend from 1990 to 2021, except for East and Central Asia, where the ASIR for CVD increased by 3% and 14.3%, respectively. Similarly, the global ASDR for CVD is only on an upward trend in sub-Saharan Africa, increasing by 12%, while all other regions are on a downward trend. Among the five SDI regions, the high SDI region has much lower ASIR and ASDR compared to the world average, and these rates have decreased significantly over the years. Conclusion Despite a significant increase in the number of CVD incident cases and deaths worldwide over the last three decades, ASIR and ASDR have been declining. Over the past 30 years, both ASIR and ASDR for CVD have declined significantly in high SDI areas, while CVD continues to pose a serious public health threat in regions with low SDI.
- 24 November 2024
- Published by Springer Nature in Cureus
- Vol. 16 (11) , e74333
Top Cited PapersOpen AccessGlobal, Regional, and National Burden of Cardiovascular Disease, 1990-2021: Results From the 2021 Global Burden of Disease Study
Background Cardiovascular diseases (CVD), including coronary artery disease, ischemic heart disease, stroke, cardiomyopathy, and atrial fibrillation and flutter, are the leading cause of mortality worldwide, resulting in significant economic and health costs. Recognizing trends and geographical differences in the global burden of CVD facilitates health authorities in particular nations to assess the disease burden and forecast future epidemiological trends. Public health authorities in each country can better understand the differences in disease data and, by learning from the experiences and practices of successful countries and considering the characteristics of their diseases, allocate health resources more rationally and formulate more targeted healthcare strategies to reduce the disease burden. This study aims to comprehensively assess CVD trends and geographic variations from 1990 to 2021. Methods This study focuses on analyzing global trends in the epidemiology of all-age CVD incidence and death over the past 30 years. A vital registration system, cause-of-death inference records, and a cause-of-death ensemble model (CODEm) were used to estimate cause-specific mortality for CVD, with CODEm estimates adjusted using a cause-of-death correction (CoDCorrect) algorithm. Incidence data were extracted from insurance claims and inpatient discharge sources and analyzed with Disease Modeling Meta-Regression, Version 2.1 (DisMod-MR 2.1). Data were extracted from the 2021 Global Burden of Disease Study (GBD 2021) on the number of incident cases and deaths, as well as age-standardized incidence rates (ASIR) and age-standardized death rates (ASDR) for CVD for each year from 1990 to 2021. We visualized and reported this data at the global, regional, and national levels. To explore the association between the burden of CVD and sociodemographic factors, we used the sociodemographic index (SDI), which categorizes the world's 204 nations into five SDI regions. Because the GBD results are a combination of data and estimates, 95% uncertainty intervals (UI) are provided for each count and rate (per 100,000 populations). Results Globally, the number of CVD incident cases and deaths increased from 34.74 million and 12.33 million in 1990 to 66.81 million and 19.42 million in 2021, representing a 92.3% and 57.5% rise, respectively. However, the global ASIR and ASDR for CVD have decreased by 10.4% and 34.3%, respectively, since 1990. Notably, among the 21 regions of the world, the ASIR for CVD is on a downward trend from 1990 to 2021, except for East and Central Asia, where the ASIR for CVD increased by 3% and 14.3%, respectively. Similarly, the global ASDR for CVD is only on an upward trend in sub-Saharan Africa, increasing by 12%, while all other regions are on a downward trend. Among the five SDI regions, the high SDI region has much lower ASIR and ASDR compared to the world average, and these rates have decreased significantly over the years. Conclusion Despite a significant increase in the number of CVD incident cases and deaths worldwide over the last three decades, ASIR and ASDR have been declining. Over the past 30 years, both ASIR and ASDR for CVD have declined significantly in high SDI areas, while CVD continues to pose a serious public health threat in regions with low SDI.
- Open Access
- 19 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (18) , e030077
Association of Magnesium Depletion Score With Cardiovascular Disease and Its Association With Longitudinal Mortality in Patients With Cardiovascular Disease
Background: Dietary magnesium and serum magnesium play an important part in cardiovascular disease (CVD). However, the association between magnesium depletion score (MDS) and CVD development and prognosis remains unclear. This analysis examines the cross‐sectional relationship between MDS and CVD, and the longitudinal association between MDS and all‐cause and CVD mortality in individuals with CVD. Methods and Results: In all, 42 711 individuals were selected from the National Health and Nutrition Examination Survey, including 5015 subjects with CVD. The association between MDS and total and individual CVDs was examined using the survey‐weighted multiple logistic regression analysis. Among 5011 patients with CVD, 2285 and 927 participants were recorded with all‐cause and CVD deaths, respectively. We applied survey‐weighted Cox proportional hazards regression analyses to investigate the impact of MDS on the mortality of individuals with CVD. The CVD group had higher MDS levels than the non‐CVD groups. After controlling all confounding factors, individuals with MDS of 2 and ≥3 had higher odds of total CVD and specific CVD than those with MDS of 0. Besides, each 1‐unit increase in MDS was strongly related to the risk of total CVD and specific CVD. The relationship between MDS and total CVD was stable and significant in all subgroups. The fully adjusted Cox regression model indicated that high MDS, irrespective of MDS as a categorical or continuous variable, was significantly associated with an elevated risk of all‐cause and CVD deaths. Conclusions: MDS is a vital risk factor for the prevalence and mortality of individuals with CVD.
- 19 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (18) , e030077
Open AccessAssociation of Magnesium Depletion Score With Cardiovascular Disease and Its Association With Longitudinal Mortality in Patients With Cardiovascular Disease
Background: Dietary magnesium and serum magnesium play an important part in cardiovascular disease (CVD). However, the association between magnesium depletion score (MDS) and CVD development and prognosis remains unclear. This analysis examines the cross‐sectional relationship between MDS and CVD, and the longitudinal association between MDS and all‐cause and CVD mortality in individuals with CVD. Methods and Results: In all, 42 711 individuals were selected from the National Health and Nutrition Examination Survey, including 5015 subjects with CVD. The association between MDS and total and individual CVDs was examined using the survey‐weighted multiple logistic regression analysis. Among 5011 patients with CVD, 2285 and 927 participants were recorded with all‐cause and CVD deaths, respectively. We applied survey‐weighted Cox proportional hazards regression analyses to investigate the impact of MDS on the mortality of individuals with CVD. The CVD group had higher MDS levels than the non‐CVD groups. After controlling all confounding factors, individuals with MDS of 2 and ≥3 had higher odds of total CVD and specific CVD than those with MDS of 0. Besides, each 1‐unit increase in MDS was strongly related to the risk of total CVD and specific CVD. The relationship between MDS and total CVD was stable and significant in all subgroups. The fully adjusted Cox regression model indicated that high MDS, irrespective of MDS as a categorical or continuous variable, was significantly associated with an elevated risk of all‐cause and CVD deaths. Conclusions: MDS is a vital risk factor for the prevalence and mortality of individuals with CVD.
- Open Access
Association of magnesium depletion score with cardiovascular disease and its association with longitudinal mortality in cardiovascular disease patients
Background Dietary magnesium and serum magnesium play an important part in cardiovascular disease (CVD). However, the correlation between magnesium depletion score (MDS) and the development and CVD prognosis remains unclear. This analysis examines the cross-sectional relationship between MDS and CVD, and the longitudinal correlation between MDS and all-cause and cardiovascular mortality in CVD individuals. Methods In all, 42,711 individuals were selected from the National Health and Nutrition Examination Survey, including 5,015 subjects with CVD. The correlation between MDS and total and individual CVD was examined using the survey-weighted multiple logistic regression analysis. Among 5,011 CVD patients, 2,285 and 927 participants were recorded with all-cause and cardiovascular deaths, respectively. We applied survey-weighted Cox proportional hazards regression analyses to investigate the impact of MDS on the mortality of CVD individuals. Results CVD group had higher MDS levels than the non-CVD groups. After controlling all confounding factors, individuals with MDS scored 1-2, and ≥3 had higher odds of total CVD and specific CVD than those with MDS scored 0. The relationship between MDS and total CVD was stable and significant in all subgroups. The fully adjusted Cox regression model presented that the risk of all-cause and cardiovascular deaths increased 2.41 and 2.00 times in participants with MDS≥3 compared to those with MDS scored 0. Conclusions MDS is a vital risk factor for CVD’s prevalence and all-cause and cardiovascular deaths. What is new? MDS is a significant positive correlation with CVD’s prevalence in US adults. High MDS markedly elevated the risk of all-cause and cardiovascular deaths among participants with CVD. What are the clinical implications? MDS can be used to evaluate the prevention and prognosis of cardiovascular diseases.
Open AccessAssociation of magnesium depletion score with cardiovascular disease and its association with longitudinal mortality in cardiovascular disease patients
Background Dietary magnesium and serum magnesium play an important part in cardiovascular disease (CVD). However, the correlation between magnesium depletion score (MDS) and the development and CVD prognosis remains unclear. This analysis examines the cross-sectional relationship between MDS and CVD, and the longitudinal correlation between MDS and all-cause and cardiovascular mortality in CVD individuals. Methods In all, 42,711 individuals were selected from the National Health and Nutrition Examination Survey, including 5,015 subjects with CVD. The correlation between MDS and total and individual CVD was examined using the survey-weighted multiple logistic regression analysis. Among 5,011 CVD patients, 2,285 and 927 participants were recorded with all-cause and cardiovascular deaths, respectively. We applied survey-weighted Cox proportional hazards regression analyses to investigate the impact of MDS on the mortality of CVD individuals. Results CVD group had higher MDS levels than the non-CVD groups. After controlling all confounding factors, individuals with MDS scored 1-2, and ≥3 had higher odds of total CVD and specific CVD than those with MDS scored 0. The relationship between MDS and total CVD was stable and significant in all subgroups. The fully adjusted Cox regression model presented that the risk of all-cause and cardiovascular deaths increased 2.41 and 2.00 times in participants with MDS≥3 compared to those with MDS scored 0. Conclusions MDS is a vital risk factor for CVD’s prevalence and all-cause and cardiovascular deaths. What is new? MDS is a significant positive correlation with CVD’s prevalence in US adults. High MDS markedly elevated the risk of all-cause and cardiovascular deaths among participants with CVD. What are the clinical implications? MDS can be used to evaluate the prevention and prognosis of cardiovascular diseases.
- 1 January 2023
- Vol. 15 (4) , 2878-2884
The relationship between peripheral blood soluble ST2, BNP levels, cardiac function, and prognosis in patients with heart failure
Objective: To analyze the relationship between peripheral blood soluble growth-stimulated expression gene 2 protein (sST2) and B-type natriuretic peptide (BNP) levels and cardiac function and prognosis in patients with heart failure (HF). Methods: HF patients (n = 183) and 50 healthy volunteers were enrolled in this retrospective study. The relationships between peripheral blood sST2 and BNP levels and cardiac function in patients with HF were analyzed by Pearson's correlation analysis. HF patients were divided into a poor prognosis group (n = 25) and a good prognosis group (n = 158) during the 1-year follow-up period, and variables that might affect the prognosis of HF patients were screened by univariate analysis. Result: The peripheral blood sST2 and BNP levels of HF patients were higher than those of healthy controls. Compared to the good prognosis group, the poor prognosis group had higher LVDs, LVDd, but lower LVEF, D-dimer, hemoglobin (HB) levels, uric acid, sST2, BNP, troponin I (TnI), creatine kinase isozyme-MB, myoglobin, creatinine (Cr), and hypersensitive C-reactive protein. LVEF, sST2, BNP, TnI, and HB were independent risk factors affecting the prognosis of patients with HF. Higher levels of peripheral blood sST2 and BNP were associated with the worse prognosis in HF. Conclusion: Peripheral blood sST2 and BNP levels in HF patients were correlated with cardiac function. LVEF, sST2, BNP, TnI, and HB were independent risk factors affecting the prognosis of HF patients, among which sST2 and BNP were all negatively correlated with prognosis.
- 1 January 2023
- Vol. 15 (4) , 2878-2884
The relationship between peripheral blood soluble ST2, BNP levels, cardiac function, and prognosis in patients with heart failure
Objective: To analyze the relationship between peripheral blood soluble growth-stimulated expression gene 2 protein (sST2) and B-type natriuretic peptide (BNP) levels and cardiac function and prognosis in patients with heart failure (HF). Methods: HF patients (n = 183) and 50 healthy volunteers were enrolled in this retrospective study. The relationships between peripheral blood sST2 and BNP levels and cardiac function in patients with HF were analyzed by Pearson's correlation analysis. HF patients were divided into a poor prognosis group (n = 25) and a good prognosis group (n = 158) during the 1-year follow-up period, and variables that might affect the prognosis of HF patients were screened by univariate analysis. Result: The peripheral blood sST2 and BNP levels of HF patients were higher than those of healthy controls. Compared to the good prognosis group, the poor prognosis group had higher LVDs, LVDd, but lower LVEF, D-dimer, hemoglobin (HB) levels, uric acid, sST2, BNP, troponin I (TnI), creatine kinase isozyme-MB, myoglobin, creatinine (Cr), and hypersensitive C-reactive protein. LVEF, sST2, BNP, TnI, and HB were independent risk factors affecting the prognosis of patients with HF. Higher levels of peripheral blood sST2 and BNP were associated with the worse prognosis in HF. Conclusion: Peripheral blood sST2 and BNP levels in HF patients were correlated with cardiac function. LVEF, sST2, BNP, TnI, and HB were independent risk factors affecting the prognosis of HF patients, among which sST2 and BNP were all negatively correlated with prognosis.
- Open Access
- 1 May 2022
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 11 (5) , 1122-1140
Mechanical property evaluation of the right ventricular myocardium in cancer patients with chemotherapy by echocardiography: a systematic review and meta-analysis
Background: Cancer therapy-related cardiotoxicity has recently become an area of intense research. As the prognostic role of the right ventricle (RV) in a variety of cardiovascular diseases has been confirmed, and several studies have paid increased attention to RV function in cancer patients who have underwent chemotherapy, we provide a meta-analysis to objectively evaluate the mechanical properties of the right ventricular myocardium by echocardiography in this population. Methods: We systematically searched Embase, PubMed, and Cochrane databases were applied to search for studies (published before August 11, 2021) comparing RV contraction measured by echocardiography at baseline to follow-up in cancer patients who underwent chemotherapy or radiotherapy. The mechanical properties of the right ventricular myocardium were pulmonary artery systolic pressure (PASP), tricuspid annular plane systolic excursion (TAPSE), systolic velocity of tricuspid annulus (S'), right ventricular free wall longitudinal strain (RVFWLS), right ventricular global longitudinal strain (RVGLS), and right ventricular fractional area change (RVFAC). We analyzed pooled data using a random-effects model and assessed risk of bias in the included studies using the Newcastle-Ottawa Scale. Results: Twenty-one trials were enrolled (N=1,355 participants). Cancer patients who underwent chemotherapy but not radiotherapy showed an increase in PASP [standardized mean difference (SMD) =0.161, 95% CI: 0.007 to 0.316) compared with the condition at baseline, as well as reductions in TAPSE (SMD =−0.543, 95% CI: −0.698 to −0.389), S' (SMD =−0.507, 95% CI: −0.748 to −0.266), RVFWLS (SMD =0.833, 95% CI: 0.549 to 1.118) and RVGLS (SMD =1.017, 95% CI: 0.751 to 1.283). There was no significant difference in RVFAC (SMD =−0.097, 95% CI: −0.213 to 0.018). Furthermore, these indicators pointed to a deterioration of right ventricular contraction function in cancer patients who underwent chemotherapy and radiotherapy. The risk of bias of the included studies evaluated by the Newcastle-Ottawa Scale was medium to high. Discussion: Right ventricular contraction function would deteriorate in cancer patients who underwent chemotherapy and radiotherapy, especially with the prolongation of chemotherapy duration and accumulation of chemotherapeutic drugs. Further studies are needed to establish the definition of right ventricular systolic dysfunction in clinical practice.
- 1 May 2022
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 11 (5) , 1122-1140
Open AccessMechanical property evaluation of the right ventricular myocardium in cancer patients with chemotherapy by echocardiography: a systematic review and meta-analysis
Background: Cancer therapy-related cardiotoxicity has recently become an area of intense research. As the prognostic role of the right ventricle (RV) in a variety of cardiovascular diseases has been confirmed, and several studies have paid increased attention to RV function in cancer patients who have underwent chemotherapy, we provide a meta-analysis to objectively evaluate the mechanical properties of the right ventricular myocardium by echocardiography in this population. Methods: We systematically searched Embase, PubMed, and Cochrane databases were applied to search for studies (published before August 11, 2021) comparing RV contraction measured by echocardiography at baseline to follow-up in cancer patients who underwent chemotherapy or radiotherapy. The mechanical properties of the right ventricular myocardium were pulmonary artery systolic pressure (PASP), tricuspid annular plane systolic excursion (TAPSE), systolic velocity of tricuspid annulus (S'), right ventricular free wall longitudinal strain (RVFWLS), right ventricular global longitudinal strain (RVGLS), and right ventricular fractional area change (RVFAC). We analyzed pooled data using a random-effects model and assessed risk of bias in the included studies using the Newcastle-Ottawa Scale. Results: Twenty-one trials were enrolled (N=1,355 participants). Cancer patients who underwent chemotherapy but not radiotherapy showed an increase in PASP [standardized mean difference (SMD) =0.161, 95% CI: 0.007 to 0.316) compared with the condition at baseline, as well as reductions in TAPSE (SMD =−0.543, 95% CI: −0.698 to −0.389), S' (SMD =−0.507, 95% CI: −0.748 to −0.266), RVFWLS (SMD =0.833, 95% CI: 0.549 to 1.118) and RVGLS (SMD =1.017, 95% CI: 0.751 to 1.283). There was no significant difference in RVFAC (SMD =−0.097, 95% CI: −0.213 to 0.018). Furthermore, these indicators pointed to a deterioration of right ventricular contraction function in cancer patients who underwent chemotherapy and radiotherapy. The risk of bias of the included studies evaluated by the Newcastle-Ottawa Scale was medium to high. Discussion: Right ventricular contraction function would deteriorate in cancer patients who underwent chemotherapy and radiotherapy, especially with the prolongation of chemotherapy duration and accumulation of chemotherapeutic drugs. Further studies are needed to establish the definition of right ventricular systolic dysfunction in clinical practice.
- Open Access
- 25 June 2021
- Published by Wiley in Clinical Cardiology
- Vol. 44 (8) , 1050-1057
Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A systematic review and meta‐analysis
Background: Atrial fibrillation (AF) is the most common cardiac rhythm disturbance and leads to morbidity and mortality. Peripheral artery disease (PAD) is associated with atherosclerotic risk factors and always classified as a vascular disease and deemed to be a bad complication of AF. In patients with AF, the risk and prognostic value of PAD have not been estimated comprehensively.Hypothesis: PAD is associated with all‐cause mortality, cardiovascular (CV) mortality, and other outcomes in patients with AF.Methods: We searched PubMed, Embase, and Cochrane Library databases for prospective studies published before April 2021 that provided outcomes data on PAD in confirmed patients with AF. Heterogeneity was estimated using the I2 statistic. The fixed‐effects model was used for low to moderate heterogeneity studies, and the random‐effects model was used for high heterogeneity studies.Results: Eight prospective studies (Newcastle‐Ottawa score range, 7–8) with 39 654 patients were enrolled. We found a significant association between PAD and all‐cause mortality (hazard ratio [HR], 1.42; 95% confidence interval [CI], 1.25–1.62; p < .001), CV mortality (HR, 1.64; 95% CI, 1.32–2.05; p < .001) and MACE (HR, 1.75; 95% CI, 1.38–2.22; p < .001) in patients with AF. No significant relationship was found in major bleeding (HR, 1.22; 95% CI, 0.95–1.57; p = 0.118), myocardial infarction (MI) (HR, 2.07; 95% CI, 1.17–3.67; p = .038), and stroke (HR, 1.14; 95% CI, 0.87–1.50, p = 0.351).Conclusions: PAD is associated with an increased risk of all‐cause mortality, CV mortality, and MACE in patients with AF. However, no significant association was found with major bleeding, MI, and stroke.
- 25 June 2021
- Published by Wiley in Clinical Cardiology
- Vol. 44 (8) , 1050-1057
Open AccessPeripheral artery disease and clinical outcomes in patients with atrial fibrillation: A systematic review and meta‐analysis
Background: Atrial fibrillation (AF) is the most common cardiac rhythm disturbance and leads to morbidity and mortality. Peripheral artery disease (PAD) is associated with atherosclerotic risk factors and always classified as a vascular disease and deemed to be a bad complication of AF. In patients with AF, the risk and prognostic value of PAD have not been estimated comprehensively.Hypothesis: PAD is associated with all‐cause mortality, cardiovascular (CV) mortality, and other outcomes in patients with AF.Methods: We searched PubMed, Embase, and Cochrane Library databases for prospective studies published before April 2021 that provided outcomes data on PAD in confirmed patients with AF. Heterogeneity was estimated using the I2 statistic. The fixed‐effects model was used for low to moderate heterogeneity studies, and the random‐effects model was used for high heterogeneity studies.Results: Eight prospective studies (Newcastle‐Ottawa score range, 7–8) with 39 654 patients were enrolled. We found a significant association between PAD and all‐cause mortality (hazard ratio [HR], 1.42; 95% confidence interval [CI], 1.25–1.62; p < .001), CV mortality (HR, 1.64; 95% CI, 1.32–2.05; p < .001) and MACE (HR, 1.75; 95% CI, 1.38–2.22; p < .001) in patients with AF. No significant relationship was found in major bleeding (HR, 1.22; 95% CI, 0.95–1.57; p = 0.118), myocardial infarction (MI) (HR, 2.07; 95% CI, 1.17–3.67; p = .038), and stroke (HR, 1.14; 95% CI, 0.87–1.50, p = 0.351).Conclusions: PAD is associated with an increased risk of all‐cause mortality, CV mortality, and MACE in patients with AF. However, no significant association was found with major bleeding, MI, and stroke.